Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY pelareorep demonstrates 69% ORR in pancreatic cancer

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 19, 2023 1:23pm

97 Views

Post# 35691229

RE:RE:RE:RE:RE:RE:ONCY pelareorep demonstrates 69% ORR in pancreatic cancer

Thus far pelareorep in combination with a checkpoint inhibitor .. ONCYs GOBLET Phase 1/2 with pelareorep reported an objective response rate (ORR) of 62% and a 6-month progression-free survival (PFS) rate of 72.9%, and a 6-month overall survival (OS) rate of 82.1% in a Phase 2 study reflective of a population of patients with mPDAC who had poor prognoses and rapidly progressing disease .

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?